FindTrial
Sign In

To find the optimal dose of the drug used for reversal of muscle paralysis which is induced by muscle relaxant given during general anaesthesia

Optimal dose of Neostigmine for effective reversal of vecuronium induced neuromuscular block based on clinical signs - A Randomised double blind clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019381
Enrollment
160
Registered
2019-05-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: administration of Neostigmine injection at a dose of 30mcg/kg: To administer 30mcg/kg of Neostigmine IV for reversal of vecuronium induced neuromuscular blockade prior to extubation whi

Sponsors

Mahatma Gandhi Medical College and Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical Status I and II

Exclusion criteria

Exclusion criteria: Patient Refusal Patients with Hepatic or Renal Dysfunction Patients with neuromuscular disorders Difficult airway Patients receiving medications which influence neuromuscular blockade

Design outcomes

Primary

MeasureTime frame
assess the incidence of drop in TOF ratio in the postoperative periodTimepoint: for 60 mins after extubation of the patient—

Secondary

MeasureTime frame
to assess the time taken to achieve TOF ratio 0.9 from the time of reversalTimepoint: after administration of reversal;To assess the TOF count and TOF ratio at 15 minute intervals of 60 minutes in the post operative periodTimepoint: 60 minutes;To assess the TOF count and TOF ratio during spontaneous attempts of breathing and exhaled tidal volume of 150 - 200mlTimepoint: at time of reversal—

Countries

India

Contacts

Public ContactDr Rani P

Mahatma Gandhi Medical College and Research Institute

anaesrani@gmail.com9443116908

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026